Cytoplasmic HuR expression has been implicated in the malignancy of colon, ovarian, breast, salivary gland, uterine, larynx and prostate cancers and has been postulated to contribute to the cancerous malignant phenotype (21–25). Here, ELAVL1 is linked to prostate carcinoma.